BioMarin's VOXZOGO Shows Promise for Treating Achondroplasia in Children

BioMarin Advances Treatment for Achondroplasia with VOXZOGO Findings

BioMarin Pharmaceutical Inc. reveals groundbreaking insights at the American Society for Bone and Mineral Research 2025 Annual Meeting, showcasing the efficacy of VOXZOGO® (vosoritide) in improving spinal morphology among children with achondroplasia. The results, derived from 14 studies including the Phase 2 CANOPY trial, underscore the treatment's potential to address significant health complications associated with this genetic disorder. In the CANOPY study, 40 children under the age of five receiving VOXZOGO for 52 weeks exhibit notable improvements in interpedicular distance (IPD) and spinal canal width across all five lumbar vertebrae when compared to a placebo control group of 27 children. These findings highlight VOXZOGO as a pivotal therapeutic option for enhancing the quality of life in young patients facing the challenges of achondroplasia.

The results further demonstrate that VOXZOGO not only promotes structural improvements in the spine but also mitigates conditions such as thoracolumbar kyphosis (TLK), which can lead to severe discomfort and disabilities. In the treated group, 57% of participants experience a reduction in TLK, compared to just 33% in the placebo cohort. Dr. Greg Friberg, BioMarin's Executive Vice President and Chief Research & Development Officer, emphasizes that VOXZOGO stands out as the only approved medication with documented benefits for spinal morphology in this patient demographic, potentially alleviating complications such as spinal stenosis. This unique profile positions VOXZOGO as a cornerstone in the management of achondroplasia, presenting a dual benefit of growth promotion and addressing significant health challenges.

Research from the Phase 3 CANOPY long-term extension study further reinforces the treatment's value, particularly for teenagers. Young men, on average starting puberty at 12.1 years, continue to benefit from VOXZOGO, achieving an impressive average growth of 24.62 cm post-puberty. This evidence supports the notion that VOXZOGO offers an ongoing therapeutic advantage beyond early childhood, making it an essential part of a comprehensive approach to treating achondroplasia. As BioMarin continues to advance its research and development efforts, the results from both CANOPY and PEGASUS studies solidify its commitment to addressing unmet medical needs in pediatric populations.

In addition to the promising results from the CANOPY study, BioMarin also presents encouraging findings from its Phase 3 PEGASUS trial, which focuses on a novel treatment for a specific genetic condition. The study highlights significant efficacy and safety profiles, revealing that a substantial percentage of participants experience improvements in their conditions. With a diverse cohort ensuring robust data representation, BioMarin aims to expedite the regulatory process for this innovative therapy, reinforcing its dedication to enhancing patient outcomes in underserved populations.

As BioMarin Pharmaceutical Inc. forges ahead with its innovative therapies, the company remains a leader in the biopharmaceutical landscape, committed to developing transformative solutions for patients with genetic disorders. The recent findings not only expand its research portfolio but also reflect a steadfast mission to improve the quality of life for individuals in need of effective treatment options.